Clinical Trial: The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis

U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT06833307) titled 'The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis' on Feb. 11.

Brief Summary: The purpose of this study is to assess efficacy, safety of subcutaneous SHR-1314 in pediatric patients of age 6 to <18 years with moderate-to-Severe plaque psoriasis

Study Start Date: Feb., 2025

Study Type: INTERVENTIONAL

Condition: Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis

Intervention: DRUG: SHR-1314

SHR-1314: dose 1 SHR-1314:dose 2 SHR-1314:dose 3

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Suzhou Suncadia Biopharmace...